OBJECTIVE: To investigate the effect of beraprost sodium, an orally active prostacyclin analogue, on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. PATIENTS AND DESIGN: Symptom limited cardiopulmonary exercise testing was performed before and 3 (1) months (mean (SEM)) after beraprost treatment in 30 patients with precapillary pulmonary hypertension (14 with primary pulmonary hypertension and 16 with chronic thromboembolic pulmonary hypertension). RESULTS: Long term treatment with beraprost resulted in significant increases (mean (SEM)) in peak workload (87 (4) W to 97 (5) W, p < 0.001) and peak oxygen consumption (peak VO2, 14.9 (0.7) ml/kg/min to 16.8 (0.7) ml/kg/min, p < 0.001). Beraprost decreased the ventilatory response to carbon dioxide production during exercise (VE-VCO2 slope, 42 (2) to 37 (1), p < 0.001). No significant difference in the responses of these variables to beraprost treatment was observed between patients with primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. CONCLUSIONS: Oral administration of beraprost sodium may improve exercise capacity and ventilatory efficiency in patients with both primary and chronic thromboembolic pulmonary hypertension.
OBJECTIVE: To investigate the effect of beraprost sodium, an orally active prostacyclin analogue, on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. PATIENTS AND DESIGN: Symptom limited cardiopulmonary exercise testing was performed before and 3 (1) months (mean (SEM)) after beraprost treatment in 30 patients with precapillary pulmonary hypertension (14 with primary pulmonary hypertension and 16 with chronic thromboembolic pulmonary hypertension). RESULTS: Long term treatment with beraprost resulted in significant increases (mean (SEM)) in peak workload (87 (4) W to 97 (5) W, p < 0.001) and peak oxygen consumption (peak VO2, 14.9 (0.7) ml/kg/min to 16.8 (0.7) ml/kg/min, p < 0.001). Beraprost decreased the ventilatory response to carbon dioxide production during exercise (VE-VCO2 slope, 42 (2) to 37 (1), p < 0.001). No significant difference in the responses of these variables to beraprost treatment was observed between patients with primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. CONCLUSIONS: Oral administration of beraprost sodium may improve exercise capacity and ventilatory efficiency in patients with both primary and chronic thromboembolic pulmonary hypertension.
Authors: L J Rubin; J Mendoza; M Hood; M McGoon; R Barst; W B Williams; J H Diehl; J Crow; W Long Journal: Ann Intern Med Date: 1990-04-01 Impact factor: 25.391
Authors: D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger Journal: Ann Intern Med Date: 2000-03-21 Impact factor: 25.391
Authors: N Nagaya; T Nishikimi; M Uematsu; T Satoh; S Kyotani; F Sakamaki; M Kakishita; K Fukushima; Y Okano; N Nakanishi; K Miyatake; K Kangawa Journal: Circulation Date: 2000-08-22 Impact factor: 29.690
Authors: S Miyamoto; N Nagaya; T Satoh; S Kyotani; F Sakamaki; M Fujita; N Nakanishi; K Miyatake Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie Journal: Expert Rev Respir Med Date: 2011-04 Impact factor: 3.772
Authors: Hans-Juergen Seyfarth; Michael Halank; Heinrike Wilkens; Hans-Joachim Schäfers; Ralf Ewert; Martin Riedel; Ernst Schuster; Hans Pankau; Stefan Hammerschmidt; Hubert Wirtz Journal: Clin Res Cardiol Date: 2010-04-25 Impact factor: 5.460
Authors: Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba Journal: J Heart Lung Transplant Date: 2010-03-15 Impact factor: 10.247